

# 2016

---

## BASE DEMAND FORECAST



Reach every child

[www.gavi.org](http://www.gavi.org)

# Introduction

---

This is the inaugural publication of the base demand forecast underlying Gavi's financial projections. This new publication is intended to improve the transparency and timeliness of demand forecasts shared with Gavi partners, industry, and the public.

The base demand forecast publication will be published each year following Gavi's December Board meeting where the financial forecast is reviewed. In general, the base demand forecast will be published in January. The precise timing could be slightly earlier or later depending on the December Board decisions that need to be integrated into the volume forecast.

The table below summarizes actual and forecasted volumes for eleven vaccines that Gavi supports. These volumes account for most of Gavi's financial expenditures on vaccines. Some smaller areas of vaccine support, for example support through stockpiles, is excluded.

The volumes presented are from the demand forecast used to inform the Gavi financial forecast. In all cases the figures include doses projected to be funded by Gavi, as well as doses co-financed by countries. In most cases, the figures also include doses projected to be fully self-financed by countries that have transitioned from Gavi support. Volumes for programmes that introduce without Gavi support (even if they are Gavi eligible) will not be included in the figures.

The countries included in a vaccine forecast will generally be those where the vaccine programme has been supported by Gavi or is forecasted to receive Gavi support in the future. There are some vaccines, for example yellow fever, where a significant number of countries have introduced without Gavi support and have not been included in this demand forecast. India and Indonesia have been excluded from the volume figures as there are a number of complexities associated with these countries that would make interpretation of the figures more difficult.

There are a number of important nuances in the volume forecast that have been footnoted to the extent possible. In general, the base demand forecast publication seeks to find a balance on describing some of the key complexities while still keeping this publication relatively simple for its intended purpose. Nevertheless, we recognize there may be additional details and explanation that will be required for some audiences and purposes. Users of this new publication can contact [forecast@gavi.org](mailto:forecast@gavi.org) if they require further guidance or information.

This first version is an initial step, with opportunities for evolution in future versions. Feedback and suggestions for improvement on this new demand forecast publication are welcomed. Please send any comments to [forecast@gavi.org](mailto:forecast@gavi.org).

# Total Volume by Vaccine, doses, millions

Vaccine	Actuals					Forecasted										Total
	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	
Pentavalent (DTP-Hib-HepB)	133	154	148	136	144	151	168	151	158	160	162	164	165	167	169	2,330
Pneumococcal conjugate vaccine (PCV)	28	48	62	107	122	139	152	136	142	144	147	148	150	151	153	1,831
Rotavirus	1	8	18	37	36	45	60	68	92	92	99	101	104	105	106	971
Measles-Rubella (MR)	0	0	88	86	32	23	57	168	269	107	133	187	155	152	141	1,597
Measles	0	10	115	22	52	28	57	12	36	7	3	2	2	0	2	349
Human papillomavirus (HPV)	0	0	1	1	2	2	10	22	25	33	35	27	40	35	40	271
Typhoid	0	0	0	0	0	0	0	0	0	51	46	45	80	51	45	318
Inactivated Polio Vaccine (IPV)	0	0	0	4	31	46	48	55	56	56	57	58	58	59	59	587
Yellow Fever (YF)	14	16	20	31	31	36	43	52	65	65	53	27	28	28	29	539
Meningitis A (MenA)	0	56	53	68	68	30	69	28	56	59	49	45	46	47	47	720
Japanese encephalitis (JE)	0	0	0	0	2	9	30	11	2	2	4	2	12	12	9	94
<b>Total of above</b>	<b>176</b>	<b>294</b>	<b>504</b>	<b>492</b>	<b>520</b>	<b>508</b>	<b>693</b>	<b>702</b>	<b>901</b>	<b>776</b>	<b>786</b>	<b>806</b>	<b>840</b>	<b>806</b>	<b>801</b>	<b>9,606</b>

## Sources

Actual volumes are based on shipment reports published by UNICEF Supply Division. Forecasted volumes are from the demand forecast consistent with the v14 Gavi financial forecast reviewed by the Gavi Board at its December 2016 meeting.

## Notes

- The figures above includes doses funded by Gavi, co-financed doses funded by countries, and doses fully self-financed by transitioned countries.
- Volumes are generally only included for programmes that have been supported by Gavi or are forecasted to be supported by Gavi; i.e. programmes that have or are expected to introduce without Gavi support are not included in the volumes.
- India and Indonesia are excluded from actual and forecasted figures. Volumes associated with Pan American Health Organization (PAHO) countries are excluded from the actuals but included in the forecasted figures (except PCV where PAHO volumes are included in both actuals and forecasted figures).
- Gavi support for IPV is based on earmarked funding for the 2014-2018 period; forecasted IPV volumes are shown for 10 years to have a consistent time horizon across the vaccines.
- YF and Meningitis rows exclude volumes associated with stockpiles.
- HPV and YF vaccine volumes incorporate decisions taken by the Gavi Alliance Board at its December 2016 meeting. The impact of these decisions for YF vaccine volumes have only been reflected in figures through 2020.

**Thank you**

---



**Reach every child**  
[www.gavi.org](http://www.gavi.org)